Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

10.78
-0.1350-1.24%
Post-market: 10.780.00000.00%16:10 EDT
Volume:154.70K
Turnover:1.66M
Market Cap:264.03M
PE:-0.91
High:10.98
Open:10.90
Low:10.46
Close:10.91
52wk High:45.00
52wk Low:10.46
Shares:24.50M
Float Shares:10.79M
Volume Ratio:1.18
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.8281
EPS(LYR):-16.0562
ROE:-93.28%
ROA:-34.18%
PB:1.13
PE(LYR):-0.67

Loading ...

Lyell Immunopharma says ronde-cel Phase 1/2 study in LBCL shows no grade 3+ CRS

Reuters
·
Jun 13

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of Lyl273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - No Difference in GCC Car T-Cell Expansion With or Without Gi Prophylaxis

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Maximum Tolerated Dose Not yet Determined

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Additional Phase 1 Data and FDA Meeting Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Lyell Immunopharma presents Phase 1/2 safety, translational data for ronde-cel in relapsed/refractory large B-cell lymphoma at EHA 2026

Reuters
·
Jun 05

Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)

TIPRANKS
·
Jun 03

Lyell Immunopharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 03

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

GlobeNewswire
·
Jun 01

Lyell Immunopharma (LYEL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Lyell Immunopharma to present at H.C. Wainwright BioConnect investor conference

Reuters
·
May 12

Lyell Immunopharma Announces Participation in May Investor Conferences

GlobeNewswire
·
May 12

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
May 07

Lyell Immunopharma Q1 revenue misses, adjusted net loss narrows

Reuters
·
May 07

Lyell Immunopharma Q1 EPS $(1.10) Beats $(2.19) Estimate, Sales $2.000K Miss $4.400K Estimate

Benzinga Earnings
·
May 07

BRIEF-Lyell Immunopharma Q1 Net Income USD -24.153 Million

Reuters
·
May 07

Lyell Immunopharma Q1 Revenue USD 2 Thousand VS. Ibes Estimate USD 4.4 Thousand

THOMSON REUTERS
·
May 07